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COX-2Cognitive impairment is commonly reported as a consequence of chemotherapy and can have consider-
able impact on everyday life on cancer patients. Thus, it is imperative to have a clear understanding of
this phenomenon and the underlying mechanism involved. In the present study we examined the role
of neuroinﬂammation and myelination in chemotherapy-related cognitive impairment. Female
Sprague–Dawley rats (12-months old) were used in the study (total n = 52, 13 rats/group). Rats were
randomly assigned to either the chemotherapy or saline control group. The drug combination of
cyclophosphamide, methotrexate, and 5-ﬂuorouracil (CMF) was given i.p. once a week for 4 weeks. Rats
in the control group received normal saline of equal volume. Animals from each group were further ran-
domized to receive either: cyclooxygenase (COX-2) inhibitor, NS-393, to block the inﬂammatory response
or vehicle. NS-398 was given at 10 mg/kg i.p. and equal volume of saline (vehicle) was injected i.p. as
vehicle. Both NS-398 and vehicle were injected 1 h after the ﬁrst CMF dose and then given daily for
28 days then rats were tested in the Y maze. Our data showed that: (1) CMF led to the increase in the
levels of inﬂammatory mediators IL-1b, TNF-a, and COX-2 while levels of the anti-inﬂammatory cytokine
IL-10 decreased; (2) cognitive impairment and neuroinﬂammation resulting from CMF persisted 4 weeks
after the treatment ended; and (3) administration of NS-398 attenuated CMF-induced neuroinﬂamma-
tion and effects on myelin and cognitive impairment. These ﬁndings suggest the involvement of neuro-
inﬂammation in CMF-induced changes in myelin and myelination, and cognitive impairment.
 2013 The Authors. Published by Elsevier Inc.Open access under CC BY license.Cognitive impairment is commonly reported as a consequence
of chemotherapy in patients with cancer [reviewed in Hodgson
et al. (2013), Janelsins et al. (2011)]. The cognitive deﬁcits reported
are impairments in memory, attention, clarity of thought, execu-
tive functioning, and speed of information processing (Ahles and
Saykin, 2002; Janelsins et al., 2010; Nelson et al., 2007). The impact
of chemotherapy-related cognitive impairment on everyday life is
considerable, with patients experiencing difﬁculty undertaking
and completing simple tasks including paying the bills and prepar-
ing meals (Boykoff et al., 2009; Reid-Arndt, 2009). Moreover,
individuals with chemotherapy-related cognitive impairmentsometimes experience difﬁculty performing necessary work-
related responsibilities (Castellon and Ganz, 2009; Reid-Arndt,
2009). Based on these reported complaints, it is clear that chemo-
therapy-related cognitive impairment can have a signiﬁcant
impact on personal, occupational, and social functioning that in
turn can contribute to decreased quality of life.
Chemotherapy-related cognitive impairment will be a signiﬁ-
cant health care concern in the future because it is estimated that
by year 2020, there will be approximately 70 million cancer
survivors worldwide (Weiss, 2008). Estimates of the prevalence
of chemotherapy-related cognitive impairment is from 16% to
85% (Correa and Ahles, 2007), a range too wide to convince those
outside the patient population of the reality of cognitive impair-
ments found in cancer patients undergoing or having completed
chemotherapy. Despite ongoing research on chemotherapy-related
cognitive impairment, an understanding of the underlying mecha-
nisms of this phenomenon is still lacking. One of the proposed
mechanisms consistently shown to be present in patients who
received chemotherapy is damage to the brain white matter micro-
structure. Neuroimaging studies show altered white matter activa-
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standard dose chemotherapy (de Ruitner et al., 2011; Kesler et al.,
2009; Silverman et al., 2007). Other studies using voxel-based
morphometry also report reductions in white matter and to some
extent gray matter in the prefrontal cortex and corpus callosum
within one year after cessation of standard dosages of chemother-
apy compared to cancer patients not receiving chemotherapy
(Inagaki et al., 2007; McDonald et al., 2010). Studies using diffusion
tensor imaging also show lower fractional anisotropy and in-
creased diffusivity in the genu region of the corpus callosum, as
well as in the frontal and temporal white matter areas two years
after standard dose chemotherapy when compared to cancer pa-
tients that did not receive the treatment and age matched healthy
subjects (Deprez et al., 2011). Also, functional magnetic resonance
imaging studies show altered activation patterns in the posterior
parietal cortex during memory encoding and executive functioning
tasks in breast cancer survivors that received chemotherapy years
earlier when compared to those that did not receive the treatment
(Koppelmans et al., 2011; Koppelmans et al., 2012).
White matter abnormalities associated with chemotherapy are
most likely due to the direct and/or indirect neurotoxicity effects of
the drugs (Weiss, 2008). Generally, the blood–brain barrier is
believed to prevent cytotoxic agents from entering the brain.
However, there are reports that demonstrate some agents such
as 5-ﬂuorouracil can cross the blood–brain barrier mainly by diffu-
sion (Sakane et al., 1999). Several preclinical studies also show that
methotrexate and cyclophosphamide when administered systemi-
cally can disrupt cell division in certain brain regions critical for
learning and memory (Briones et al., 2011; Seigers et al., 2008;
Seigers et al., 2010a). Reports on mice show that 5-ﬂuorouracil
can damage myelin-forming oligodendrocytes and their precursor
cells (Dietrich et al., 2006; Han et al., 2008). These reports point to
the vulnerability of oligodendrocytes to the toxic effects of
chemotherapeutic agents as a possible reason for the white matter
abnormalities seen in imaging studies. However, the mechanism
that mediates the toxic effects of chemotherapy on oligodendro-
cytes remains unclear.
Neuroinﬂammation begins as a host defense mechanism associ-
ated with neutralization of an insult and restoration of normal
structure and function (Finnie, 2013). On the other hand, if neuro-
inﬂammation is not regulated, it can result in a self-propagating
and deleterious process (Block and Hong, 2005). Microglial cells
are considered to be the resident immune system of the brain
and initiate the neuroinﬂammatory process as a reaction to various
insults (Woodcock and Morganti-Kossman, 2013) including chem-
ical insults, induced by chemotherapy. Persistent neuroinﬂamma-
tion results in chronically activated microglia and release of
inﬂammatory mediators such as tumor necrosis factor-alpha
(TNF-a) and interleukin1-beta (IL1-b) that may lead to neuronal
and glial cell damage. In the present study we examined the role
of neuroinﬂammation and myelination in chemotherapy-related
cognitive impairment.1. Methods
1.1. Animal model
Female Sprague–Dawley rats (12-months old) obtained from
Harlan Laboratories (Madison, Wisconsin) were housed in pairs
in a pathogen-free vivarium under controlled condition (tempera-
ture 22 ± 1 C and humidity 70 ± 5%) and a 14:10 h light:dark cycle
was maintained. All animals were housed in the same room so that
temperature, humidity, and lighting conditions were similar for all
groups. Animals had free access to food (regular rat chow) and
water delivered through an automated and ﬁltered system. Ani-mals were also handled daily throughout the study so that they
could get acclimated to the research personnel thereby decreasing
stress. Experiments started 1 week after arrival of the animals from
the breeder and all experimental protocols in this study were
approved by the Institutional Animal Care and Use Committee
and in accordance with the National Institutes of Health guidelines.
We conducted a series of experiments using different rat groups for
a total n = 52 (13 rats/group).
1.2. Chemotherapeutic regimen
Rats in the chemotherapy group received the drug combination
of cyclophosphamide (40 mg/kg; Sigma–Aldrich), methotrexate
(37.5 mg/kg; Wyeth Ayerst, Itasca, IL), and 5-ﬂuorouracil (75 mg/
kg; Sigma–Aldrich) dissolved in normal saline. Rats in the control
group received normal saline of equal volume to control for the
effects of stress induced by the injection. The dosages selected
were based on our preliminary work, which showed that animals
tolerated these doses with minimal weight loss or death (Briones
and Woods, 2011). Both CMF and normal saline injections were gi-
ven intraperitoneally once a week for a total of 4 weeks and rats
were weighed every other day during the chemotherapeutic
regimen. Rats were also monitored daily for other possible toxicity
effects of chemotherapy such as apathy, excessive grooming, motor
impairment, hair loss, and diarrhea (n = 2).
1.3. Drug administration
A cyclooxygenase-2 (COX-2) inhibitor was given to block the
inﬂammatory response. COX-2 is a key synthetase of prostaglandin
E2, a ubiquitous central proinﬂammatory mediator, which acts on
the brain. We used the selective COX-2 inhibitor, NS-398 (Cayman
Chemical, Ann Arbor, MI). The COX-2 inhibitor, NS-398, was
dissolved in saline and given at 10 mg/kg i.p. For the control group,
equal volume of saline (vehicle) was injected i.p. Both NS-398 and
vehicle were injected one hour after CMF administration and then
given daily for 28 days (4 weeks) thereafter.
1.4. Behavioral testing
Spontaneous object recognition and temporal order memory
were tested using the Y maze as previously described (Briones
and Darwish, 2012). Rats were habituated to the Y maze without
any objects for 1 min per day for 3 days to reduce anxiety. Tests
in the Y maze consisted of: novel object preference, object-in-
place, and temporal order memory tasks. Brieﬂy, all tests com-
prised of an acquisition phase (sample phase) and a recognition
phase (test phase), separated by a time delay. The maze and objects
were wiped with a wet cloth containing sodium hypochlorite solu-
tion after each session to eliminate odor cues. Exploratory behavior
was deﬁned as the animal directing its nose or snifﬁng toward the
object at a distance of 2 cm. Behaviors such as looking around
while sitting on or resting against the object were not considered
exploratory behavior.
The novel object recognition task allowed discrimination be-
tween novel and familiar objects. This kind of memory consisted
of two components: recollection, which depends on the hippocam-
pus, and familiarity, which depends on the perirhinal cortex
(Barker and Warburton, 2011). The delay between the sample
and test phases was 30 min. The time spent exploring the novel
and familiar objects was recorded for 2 min but attention was
focused on the ﬁrst minute, during which rats’ preference for the
novel object is typically greatest (Mumby et al., 2002). The position
of the objects in the test phase and the objects used as novel or
familiar were counterbalanced between rats.
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novel object recognition test. In this task, the rat’s ability to
recognize objects it had experienced before that remained in the
same location versus those that had changed location was as-
sessed. The delay between the sample and test phases was
60 min and the objects were moved and the positions of the ob-
jects were counterbalanced between rats. If object-in-place mem-
ory is intact, the animal should spend more time exploring the
two objects that are in different locations compared to the two ob-
jects that are in the same locations.
Temporal order memory task was started 24 h after completion
of the object-in-place test. This task comprised of two sample
phases and one test trial. Different objects were used for sample
phases 1 and 2, with a delay between the sample phases of
30 min. The test trial (2 min duration) was given 90 min after sam-
ple phase 2. The positions of the objects in the test and the objects
used in sample phases 1 and 2 were counterbalanced between the
animals. If temporal order memory is intact, the rats should spend
more time exploring the object from sample 1, i.e., the object pre-
sented less recently, compared with the object from sample 2, i.e.,
the new object.
In all the tasks, the rats were placed in the Y maze start box and
the guillotine door was opened to allow the rat entry into the main
area of the apparatus; the door was closed immediately once the
rats had vacated the start box to prevent reentry into this area.
Timing of the exploration session did not begin until the rat had
exited the start box. The Y shape maze was used to reduce the spa-
tial and contextual information and test only object recognition
abilities of the animals. All sessions (acquisition and testing) were
recorded using the Ethovision XT v.8.5 video tracking program
(Leesburg, VA). The total time exploring each object and the dis-
crimination ratio, which is the difference in time exploring novel
and familiar objects divided by the total time were calculated.
1.5. Tissue preparation
All rats were euthanized using CO2 asphyxiation after behav-
ioral testing, the brains removed, cut in half sagitally and the cor-
pus callosum was manually dissected then immediately placed in
liquid nitrogen and kept frozen until processed. One half was used
for immunohistochemistry (oligodendrocyte progenitor cells and
myelin basic protein). The other half was used for ELISA and Wes-
tern blot for determination of cytokines IL-1b and TNF-a protein
levels, and COX-2 expression, respectively. A subset of animals
(n = 5/group) was used to examine myelin structure (myelinated
and unmyelinated axons and myelin thickness) and the brains
were prepared for electron microscopy. Blinding procedures were
employed in all experimental protocols.
1.6. Cytokine protein quantiﬁcation
The concentration of IL-1b, TNF-a, and IL-10 protein levels was
determined in the corpus callosum using commercially available
ELISA assays, following the instructions supplied by the manufac-
turer (R&D Systems; Minneapolis, MN). Brieﬂy, 0.2 g of frozen cal-
losal tissue was homogenized with a glass homogenizer in 1 ml
buffer containing 1 mmol/liter phenylmethylsulfonyl ﬂuoride,
1 mg/liter pepstatin A, 1 mg/liter aprotinin, and 1 mg/liter leupep-
tin in PBS (pH 7.2) and centrifuged at 12,000g for 20 min at 4 C.
The supernatant was collected and total protein was determined
by bicinchoninic acid (BCA) protein assay reagent kit (PIERCE, Mil-
waukee, WI). Samples were used for ELISA to determine IL-1b, TNF-
a, and IL-10 protein levels. The procedure was performed accord-
ing to manufacturer’s speciﬁcation using the Quantikine rat-spe-
ciﬁc ELISA kits (R&D Systems, Minneapolis, MN) and the color
reaction was detected using the chromogen tetramethylbenzidine.Color reaction was stopped by an equal volume of stop solution
(provided by the manufacturer) and read in a microplate reader
(Bio-Tek, Winooski, VT) at a wavelength of 450 nm (650-nm refer-
ence wavelength). The color change was proportional to the con-
centration of the cytokines measured and all samples measured
were within the range of the standard curve. This ELISA system de-
tects both natural and recombinant rat IL-1b, TNF-a, and IL-10.
Assays were sensitive to 5 pg/ml for IL-1b and TNF-a, and 10 pg/
ml for IL-10; the intra-assay and inter-assay coefﬁcients of varia-
tion were <5% and <10% for TNF-a and IL-10, and <6% and <9%
for IL-1b. Assays were performed in triplicates and measurements
were averaged and used as one individual data point for statistical
analysis.
1.7. Western Blot
To detect COX-2 levels 0.5 g of frozen callosal tissue was used in
theWestern blot procedure. Tissues were homogenized and centri-
fuged at 25,000g for 20 min as previously described (Briones et al.,
2006; Briones et al., 2009). Aliquots from the supernatant were re-
moved for protein determination. Protein concentration in samples
was determined using the BCA-Protein assay (Pierce, Rockford, IL).
Equal amounts of protein (40 lg) from each rat were loaded and
separated by SDS–PAGE gel electrophoresis in 8–16% acrylamide
gradient gels. The protein bands were electrophoretically trans-
ferred to nitrocellulose membranes (Amersham, Piscataway, NJ)
stained with 0.5% Ponceau Red to visualize total proteins, then
destained. Non-speciﬁc binding sites were blocked then nitrocellu-
lose membranes were incubated overnight at 4 C with gentle agi-
tation in the primary antibody goat anti-COX-2 (1:1000, Santa Cruz
Biotechnology, Santa Cruz, CA). The secondary antibodies used
were horseradish peroxidase-conjugated immunoglobulin (Sigma,
St. Louis, MO) and the Super Signal chemiluminescense substrate
kit (Pierce, Rockford, IL) was used to visualize immunoreactive
bands. After visualization, the membranes were then stained with
Amido-Black to qualitatively verify protein loading. A series of
dilutions were performed and immunoblotted for each antibody
to establish that the relationship between protein band and inten-
sity was linear over the range of band intensities observed in the
samples. Band visualization was obtained by exposure of mem-
branes to autoradiographic ﬁlm (Kodak Biomax™). Samples were
analyzed in quadruplicates and measurements were averaged
and used as one individual data point for statistical analysis. Quan-
tiﬁcation of differences in protein bands between samples was
done using densitometric analysis (Scion Image Beta 4.0.2; Freder-
ick MD). The internal control b-actin was used to standardize
experimental values in densitometric analysis. Densitometric val-
ues were calculated as: density of sample band / density of
background.
1.8. Electron microscopy
Animals were anesthetized with pentobarbital (100 mg/kg) and
transcardially perfused with 100 ml of heparinized 0.1 M phos-
phate buffer (pH 7.3) followed by 50 ml of sodium cacodylate buf-
fer (pH 7.3) then 400 ml of ﬁxative (2% glutaraldehyde and 2%
paraformaldehyde in the same buffer). After perfusion, the whole
brain was immediately removed and kept in ﬁxative at 4 C over-
night. Following postﬁxation, a midsagittal cut made, and a
1 mm thick slab containing the anterior third of the corpus callo-
sum from the right hemisphere was isolated. The tissue was post-
ﬁxed with buffered 2% osmium tetroxide, treated en bloc with
uranyl acetate, gradually dehydrated in ethanol/propylene oxide,
and embedded in an Araldite/Epon resin mixture (Ted Pella, Redd-
ing, CA). The blocks were coded to preclude experimenter bias dur-
ing quantitative morphological analysis. To ensure consistency
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section thickness, tissue from all groups was processed together for
each step of histological processing. Semithin sections (1 lm) were
taken from the embedded blocks using an ultramicrotome then
mounted on gelatin-coated slides and stained with Toluidine blue
then coverslipped. An outline of the callosal genu region was
traced using a camera lucida (Fig. 1) and the area of the genu
was determined using the ImageJ software (v. 1.47).
Using the 1 lm sections as a guide, a pyramid was trimmed
from the same block so that only the genu occupy the sectioned
area. Ultrathin sections (60–75 nm) were cut from embedded tis-
sue blocks containing the genu using an ultramicrotome and
mounted on formvar-coated grids, which were then stained with
uranyl acetate and lead citrate and examined using a Philips
CM200 transmission electron microscope. Myelinated and unmy-
elinated axon quantiﬁcation was performed employing the stereol-
ogical point counting technique using a grid that has a known
number of intersections or points (110 intersection) placed ran-
domly over the digital electron micrographs. The area occupied
by the structure of interest (myelinated and unmyelinated axons)
was approximated by the number of intersections that falls upon
that structure summed over all sampled images (6 images/rat)
multiplied by the area of interest (genu region determined from
the Toluidine Blue-stained scanned images). In addition, myelin
sheath thickness of counted axons were determined using the Im-
ageJ software and myelin thickness measurements were made
from portions of individual sheaths without artifactual disruption
of lamellae.1.9. Immunohistochemistry
For immunohistochemistry, the ﬁxed brains (ﬁxative is 4% para-
formaldehyde in 0.1 M phosphate buffer, pH 7.3) were sectioned at
20 lm thickness using a cryostat. The free-ﬂoating sections were
ﬁrst treated with 0.3% hydrogen peroxide in PBS to inactive endog-
enous peroxidase activity. After inactivation, the tissues were
rinsed and placed in the blocking solution of 3% serum, 0.1% Tri-
ton-X, and 1% bovine serum albumin for 1 h then washed in
0.1 M phosphate buffered saline (pH 7.3) followed by incubation
for 48 h at 4 C with antibody recognizing either: (1) oligodendro-
cyte precursor cells with O4 antigens (monoclonal anti-mouse,
1:1000); or (2) myelin basic protein (monoclonal anti-mouse,
1:1500). The primary antibodies (Chemicon International, Temecu-
la, CA) were detected using biotinylated IgG secondary antibodies
(1:400, Vector Laboratories, Burlingame, CA) for 1 h at room tem-
perature. The tissues were then washed and incubated in avidin–
biotin complex (ABC kit, Vector Laboratories, Burlingame, CA) for
one hour at room temperature. Immunoreactions were visualized
by treatment of tissue sections with hydrogen peroxide and 3,3’-
diaminobenzidine tetrahydrochloride (DAB) in Tris buffer
(pH 7.3) enhanced with nickel. After thorough rinsing, the tissue
sections were mounted on gelatin-coated slides, dried, and covers-
lipped. Tissues from all experimental groups were run simulta-
neously and under identical conditions to ensure reproducibilityFig. 1. Camera Lucida drawing of the corpus callosum. The region sampled in the
study for electron microscopy was the genu.of results. In all immunohistochemical experiments, pre-dilution
test were done to ensure speciﬁcity of the antibodies and negative
controls, involving deletion of the primary antibodies, were used to
rule out any nonspeciﬁc interactions.
The stereological method of surface density (Sv) measurements
was used to quantify OPC and myelin immunoreactivity wherein a
set of test lines (cycloid arcs) was superimposed on light micro-
scopic images and the intersection between the test lines and
immunoreactive cells were counted. Surface density was calcu-
lated using the formula: Sv = 2(I/L), where I is the total number
of intersections, summed over all samples (6 samples/animal),
and L is the total length of the test line within the sample area
(502 lm).
1.10. Statistical analysis
The SAS general linear model (SAS Institute, North Carolina)
procedures for two-way analysis of variance (ANOVA) were used
to examine effects of experimental conditions (CMF vs. saline
groups) and COX-2 inhibitor (NS-398 vs. vehicle) on the dependent
variables. Two-way repeated measures ANOVA was used to exam-
ine CMF and COX-2 inhibitor effects on behavioral performance on
the Y maze. When appropriate, the SAS CONTRAST statement was
used for planned comparisons. All error bars represented ± stan-
dard error of the mean (SEM) of the sample size used in the study.2. Results
The main goal of the study was to determine the link between
changes in myelination and neuroinﬂammation as potential mech-
anisms in chemotherapy-induced cognitive impairment. We exam-
ined the effects of CMF-induced neuroinﬂammation on
oligodendrocyte precursor cells (OPCs) and myelin basic protein
in the corpus callosum; as well as on myelinated and unmyelinated
axons, and myelin sheath thickness in the genu of the corpus cal-
losum. The genu was chosen for electron microscopy analysis be-
cause ﬁbers from this area connects the two hemispheres of the
prefrontal cortex, brain region involved in working memory (van
der Knapp and van der Ham, 2011), which is the most common
deﬁcit reported in chemotherapy-related cognitive impairment
(Hodgson et al., 2013; Janelsins et al., 2011).
2.1. Chemotherapy induces persistent neuroinﬂammation
Initially we examined the effects of CMF on the persistent neur-
oinﬂammatory response. For this purpose, rats were randomly as-
signed to either CMF or saline therapy then animals from each
group were further randomized to receive either NS-398 (COX-2
inhibitor) or vehicle. After 4 weeks of therapy, rats were allowed
to recover for another 4 weeks then tested in the Y maze followed
by euthanasia. We examined protein levels of the pro-inﬂamma-
tory cytokines IL-1b and TNF-a using ELISA and expression of
COX-2 using Western blot. Our results indicated signiﬁcant main
effects on IL-1b (F(3,48) = 9.88, p < 0.05), TNF-a (F(3,48) = 10.06,
p < 0.05), and COX-2 (F(3,48) = 11.14, p < 0.05) where CMF treat-
ment led to the upregulation of these inﬂammatory mediators
even when therapy was discontinued 4 weeks before euthanasia
(Fig. 2A–C). However, giving COX-2 inhibitor immediately after
the initial CMF treatment signiﬁcantly decreased levels of IL-1b,
TNF-a, and COX-2 in the corpus callosum to 25%, 39%, and 34%,
respectively, when compared to the CMF-treated animals that re-
ceived vehicle. No signiﬁcant changes were seen in IL-1b, TNF-a,
and COX-2 levels in the saline-treated rats.
In addition, we also examined levels of IL-10 and found signiﬁ-
cant main effects of CMF (F(3,48) = 10.99, p < 0.05) and NS-398
Fig. 2. Expression of Inﬂammatory markers in the Corpus Callosum. ELISA showed signiﬁcant increase in IL-1b (A), TNF-a (B), and COX-2 (C) after CMF treatment but
administration of COX-2 inhibitors lessened the upregulation of these inﬂammatory mediators. ELISA also showed that CMF treatment resulted in decrease levels of the anti-
inﬂammatory cytokine IL-10. No signiﬁcant differences were seen in the saline-treated groups. Representative Western blot is shown on the upper panel (C). Legends:
1 = CMF/NS-398; 2 = CMF/vehicle; 3 = Saline/NS-398; 4 = Saline/vehicle. ⁄p < 0.05, ⁄⁄p < 0.01.
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of this anti-inﬂammatory cytokine was seen 4 weeks after CMF
treatment was discontinued. But administration of COX-2 inhibitor
immediately after the ﬁrst dose of CMF treatment signiﬁcantly
modulated the reduction of IL-10 levels. IL-10 levels in the CMF-
treated rats that received NS-398 was 36% higher when compared
to the CMF-treated animals that received vehicle. No signiﬁcant
differences were seen in IL-10 levels in the saline-treated rats
(Fig. 2D). Together, these results suggest that neuroinﬂammation
occurred in response to CMF and that it can persist even after dis-
continuation of treatment.
2.2. Chemotherapy induces persistent cognitive impairment
Rats were allowed to recover for 4 weeks after CMF or saline
treatment then behavioral testing was performed in the Y maze.
Analysis of performance in the novelty recognition task showed no
signiﬁcant main effects of CMF and NS-398 in exploration times
during the acquisition phase. Separate analysis of exploration
times in the test phase also showed no signiﬁcant group differ-
ences as seen in Table 1. Moreover, discrimination ratio on the test
phase showed no signiﬁcant main effect of CMF nor NS-398 where-
in all rats demonstrated the ability to discriminate between the
familiar and novel objects even after a time delay between the
acquisition and test phases (Fig. 3A). Also, no signiﬁcant interaction
effect was seen between CMF and NS-398 in total exploration
times and discrimination ratio.Evaluation of performance in the object-in-place task showed no
signiﬁcant group differences in exploration time after a 30 min
delay (Table 1). But signiﬁcant main effects of CMF
(F(3,48) = 10.18, p < 0.05) and NS-398 (F(3,48) = 12.30, p < 0.05)
were seen in discrimination ratio where the ability to discriminate
between the moved object and the object that remained in place
was lower in the CMF-treated rats (Fig. 3B). However, this cogni-
tive impairment was mitigated in the CMF-treated animals that re-
ceived NS-398 even though their discrimination ratio was still less
than the saline-treated animals. Comparison of the saline-treated
groups showed no signiﬁcant difference in discrimination ratio in
the object-in-place task.
Analysis of recognition in the temporal order memory test after a
90-min delay revealed signiﬁcant main effects of CMF
(F(3,48) = 12.11, p < 0.05) and NS-398 (F(3,48) = 11.99, p < 0.05) in
exploration time as seen in Table 1. Post hoc testing conﬁrmed that
exploration time of the CMF-treated rats that received vehicle was
signiﬁcantly worse when compared to all groups (Table 1). But
CMF-treated rats given NS-398 showed improvement in explora-
tion time when compared to the CMF-treated group that received
vehicle even though their performance is still impaired in compar-
ison to the saline treated groups. No signiﬁcant difference was seen
in exploration time between the saline-treated groups. Analysis of
discrimination ratio also showed signiﬁcant main effects of CMF
(F(3,48) = 12.11, p < 0.05) and NS-398 (F(3,48) = 11.80, p < 0.05)
where CMF-treatment resulted in decrease ability able to discrim-
inate between the objects presented earlier and the one presented
Table 1
Exploration time in the Y maze. Mean exploration time expressed in seconds during the sample and test phases in the novelty recognition test, and during the test phases in the
object-in-place and temporal order memory tests. No signiﬁcant differences were seen in exploration time during the novelty recognition task. Meanwhile, CMF-treated rats
showed signiﬁcantly decrease exploration time in the object-in-place and temporal order memory tests after a time delay overall. Although performance improvement was seen
in the CMF-treated rats given NS-398, they still showed signiﬁcantly decrease exploration time when compared to the saline-treated animals. No signiﬁcant differences were seen
in the saline groups.
Novel object preference Object-in-place Temporal order memory
Sample phase (s) Test phase (s) Test phase (s) Test phase (s)
CMF/NS-398 42.7 ± 2.71 44.1 ± 2.91 21.5 ± 3.47* 23.3 ± 2.60*
CMF/vehicle 44.2 ± 2.13 47.3 ± 2.83 14.2 ± 2.72** 13.1 ± 2.41**
Saline/NS-398 45.8 ± 1.99 46.2 ± 3.01 31.7 ± 2.14 30.1 ± 2.26
Saline/vehicle 47.3 ± 1.87 46.5 ± 2.72 29.9 ± 2.40 31.9 ± 2.11
* p < 0.05.
** p < 0.01.
Fig. 3. Behavioral performance in the Y maze. Discrimination ratio in the novelty object test (A) showed no signiﬁcant differences in all groups. However, CMF rats showed
signiﬁcant impairment in discriminating between the objects presented in the object-in-place test (B) and temporal order memory test (C) compared to the saline group but
administration of NS-398 ameliorated the CMF-induced cognitive impairment. However, performance of the CMF-treated rats given NS-398 is still impaired in the objecy-in-
place and temporal order memory task when compared to the saline group. No signiﬁcant differences were seen in the performance of the saline groups. ⁄p < 0.05, ⁄⁄p < 0.01.
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rats that received NS-398 performed 80% better than the CMF
group that received vehicle. But administration of NS-398 to the
CMF group did not completely eliminate the cognitive deﬁcit in
the temporal order memory task when compared to the saline-
treated rats. Together, these results suggest that cognitive impair-
ment persisted even after discontinuation of treatment and that
modulating the inﬂammatory response may be able to ameliorate
CMF-related cognitive impairment.
2.3. Chemotherapy induces myelination and myelin abnormalities
Next we aimed at evaluating the involvement of chemotherapy
and neuroinﬂammation on structural changes in myelin and mye-
lination. Our results showed a signiﬁcant main effect of CMF
(F(3,48) = 10.43, p < 0.05) and NS-398 (F(3,48) = 11.01, p < 0.05) in
O4 immunoreactivity. As well, a signiﬁcant main effect of CMF(F(3,48) = 12.08, p < 0.05) and NS-398 (F(3,48) = 10.91, p < 0.05)
was seen in myelin basic protein immunoreactivity (Fig. 4).
Signiﬁcant decreased in O4 and myelin basic protein (MBP) immu-
noreactivities were seen after CMF treatment; but post hoc com-
parisons showed that administration of NS-398 signiﬁcantly
attenuated the reduction in O4 and MBP immunoreactivities in-
duced by CMF. Yet NS-398 administration did not completely stop
the CMF-induced loss in O4 and MBP immunoreactivities. No sig-
niﬁcant differences in O4 and MBP immunoreactivities were seen
in the saline-treated groups.
When we examined the myelin structure, we found a signiﬁcant
main effect of CMF and NS-398 in the area of the genu covered by
myelinated axons (Fig. 5). Additionally, a signiﬁcant main effect of
CMF (F(3,48) = 11.05, p < 0.05) and NS-398 (F(3,48) = 10.78,
p < 0.05) was seen in the area of the genu covered by unmyelinated
axons. CMF treatment resulted in decreased area of the genu cov-
ered by myelinated axons while the area covered by unmyelinated
Fig. 4. O4 pre-myelinating cells and myelin basic protein (MBP) expression. CMF treatment resulted in decrease O4 (lower left) and MBP (lower right) immunoreactivities in
the corpus callosum, but administration of NS-398 diminished the cytotoxic effects of the chemotherapy on O4 and MBP. However, CMF-treated rats that received NS-398
still showed a reduction in both OPCs and MBP compared to the saline-treated rats. Representative photomicrographs of O4 and MBP immunoreactions in the corpus
callosum (upper panel). ⁄p < 0.05, ⁄⁄p < 0.01. Scale bar = 20 lm.
Fig. 5. Axon myelination and thickness. CMF treatment resulted in decrease area occupied by myelinated axons (A) and increased area occupied by unmyelinated axons (B) in
the genu region of the corpus callosum, but administration of NS-398 diminished the cytotoxic effects of the chemotherapy on myelination. However, CMF-treated rats that
received NS-398 still show decreased myelinated axons and increased unmyelinated axons compared to the saline-treated rats. No signiﬁcant groups differences were seen in
the saline-treated animals. Similar pattern of CMF and NS-398 effects were seen when myelin thickness was measured (D). Representative digital electron micrographs (C)
showing myelinated axons (arrows) and unmyelinated axons (arrowhead). ⁄p < 0.05, ⁄⁄p < 0.01. Scale bar = 1 lm.
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isons showed that administration of NS-398 to CMF-treated rats
signiﬁcantly reduced the chemotherapy-induced myelin loss;
although the area occupied by myelinated and unmyelinated axons
in the CMF-treated rats that received NS-398 was still signiﬁcantly
decreased in relation to the saline-treated animals.
Quantiﬁcation of the thickness of myelin sheath in the genu re-
gion of the corpus callosum also showed signiﬁcant main effects of
CMF (F(3,48) = 10.14, p < 0.05) and NS-398 (F(3,48) = 10.32,
p < 0.05). Overall, myelin sheath thickness was signiﬁcantly less
in the CMF rats given vehicle but posthoc comparisons showed
that giving NS-398 to CMF-treated rats during and after treatment
signiﬁcantly attenuated the decrease in myelin sheath thickness.
However, myelin sheath thickness in the CMF-treated rats given
NS-398 still showed signiﬁcantly less thickness in their myelin
sheath thickness when compared to the saline-treated groups.
No signiﬁcant differences were seen in myelin sheath thickness
in the saline-treated groups. Together, these results suggest the
involvement of neuroinﬂammation in CMF-induced effects on
myelination and myelin structure.3. Discussion
In the present study we show that CMF therapy results in per-
sistent neuroinﬂammation, and that neuroinﬂammation is in-
volved in CMF-induced cognitive dysfunction and changes in
myelin structure and myelination. These ﬁndings are supported
by our data that: (1) CMF therapy led to the increase in levels of
inﬂammatory mediators IL-1b, TNF-a, and COX-2 while levels of
the anti-inﬂammatory cytokine IL-10 decreased; (2) both cognitive
impairment and neuroinﬂammation resulting from CMF therapy
persisted 4 weeks after the treatment ended; and (3) administra-
tion of the COX-2 inhibitor, NS-398, attenuated CMF-induced neur-
oinﬂammation, effects on myelination, and cognitive impairment.
Ultimately, these ﬁndings suggest the intricate involvement of
neuroinﬂammation in CMF-induced structural effects in the corpus
callosum and cognitive impairment; and to our knowledge this is
the ﬁrst study to address this area of investigation.
Neuroinﬂammation is an important compensatory mechanism
of the brain when it encounters an insult where an upregulation
of inﬂammatory mediators are triggered (Block and Hong, 2005).
As a compensatory mechanism following an insult, neuroinﬂam-
mation has clear beneﬁcial effects only if it is controlled in a regu-
lated manner and for a deﬁned period of time (Finnie, 2013).
However, if the neuroinﬂammatory process persist it can contrib-
ute to neurodegeneration and neurological impairments (Lucin
and Wyss-Coray, 2009). Our data on upregulation of the inﬂamma-
tory mediators IL-1b, TNF-a, and COX-2 together with down
regulation of the anti-inﬂammatory cytokine IL-10 weeks after
discontinuation of CMF treatment suggest the persistent nature
of neuroinﬂammation induced by the cytotoxic effects of chemo-
therapy. These results are in contrast with a previous study that re-
ported decrease plasma cytokine expression while no increase in
central cytokine levels seen following methotrexate treatment in
rats (Seigers et al., 2010b). A possible explanation for the contrast-
ing ﬁndings is that our study used the combination treatment of
cyclophosphamide, methotrexate, and 5-ﬂuorouracil while the
other study used methotrexate alone. Therefore, it is possible that
the addition of cyclophosphamide and 5-ﬂuorouracil increased the
cytotoxicity levels of the chemotherapeutic regimen used in the
present study since an earlier report show that 5-ﬂuorouracil alone
can cause damage to oligodendrocytes (Dietrich et al., 2006; Han
et al., 2008). Furthermore, decreased levels of pro-inﬂammatory
cytokines reported in the other study are in conﬂict with our data
on increased IL-1b and TNF-a. This difference may be explained bythe fact that we measured central expression of pro-inﬂammatory
cytokines in the corpus callosum while the other study measured
plasma levels. It is highly likely that cytokine expression in the
brain will differ from peripheral expression in plasma.
The vulnerability of both cerebral white and gray matters to the
cytotoxic effects of chemotherapy have been well document in
neuroimaging studies [reviewed in (Simo et al., 2013)]. For exam-
ple, reports show late effects (10 years) of high-dose adjuvant che-
motherapy on white matter structure (decreased fractional
anisotropy and increased diffusivity) in breast cancer survivors
(de Ruitner et al., 2011). Others also report decreased white matter
tracts in cancer survivors given standard-dose chemotherapy from
months to years after treatment (Abraham et al., 2008; Deprez
et al., 2011). White matter is composed of myelinated axons and
oligodendrocytes. The O4 cells examined in the present study are
pre-myelinating precursor cells formed postnatally (Schachner
et al., 1981) and is a marker for cell bodies and processes of oligo-
dendrocytes types I and II. During oligodendrocyte differentiation,
O4 occurs in pro-oligodendrocytes, but not in O-2A-progenitor
cells, thus it is commonly used in myelination, demyelination
and remyelination studies. MBP on the other hand is a major struc-
tural protein of myelin sheaths (Baumann and Pham-Dinh, 2001).
In the present study, we examined the corpus callosum because
it is the largest white matter structure in the brain and is primarily
comprised of both myelinated and unmyelinated axons. Myelin
structures are formed by oligodendrocytes and our data suggest
the possibility of chemotherapy-induced impairment in myelin
formation. This logic is reﬂected on our results on decreased O4
immunoreactivity and validated by a previous study showing the
cytotoxic effects of 5-Fluorouracil on oligodendrocytes (Dietrich
et al., 2006; Han et al., 2008). Our results showing decreased
MBP immunoreactivity provide further support on the vulnerabil-
ity of white matter structures to the cytotoxic effects of chemo-
therapy since this protein directly correlates with levels of
myelination (Campagnoni and Maeklin, 1988). Our ﬁndings are
also in line with a previous report on delayed white matter degen-
eration in rats after treatment with 5-Fluorouracil (Han et al.,
2008). The persistent neuroinﬂammation seen in our study most
likely explain CMF-induced changes in myelination and myelin
structure. What is not clear from the present study is whether
the neuroinﬂammation and myelination changes seen after
4 weeks of chemotherapy is a delayed effect or an acute response
that persisted during the recovery period. This issue warrants
further investigation in future studies.
Our data on decreased area occupied by myelinated axons while
area occupied by unmyelinated axons increased associated with
CMF treatment are also not surprising. These ﬁndings together
with the decreased thickness in myelin sheaths seen in the
CMF-treated rats may be explained by the reduction in MBP levels.
MBP constitutes 25% of the myelin in the central nervous system
and has been documented to be involved in the myelination
process and the compaction of myelin sheath. Interestingly, block-
ing the neuroinﬂammatory response to CMF treatment offset the
detrimental effects of chemotherapy on myelin and the myelina-
tion suggesting a direct link between CMF-induced neuroinﬂam-
mation and myelin breakdown.
The present study also reinforces previous reports on the rela-
tionship between myelin structure changes and cognitive impair-
ment. Our data show that CMF-induced decrease in OPCs and
MBP immunoreactivities as well as reduction in myelinated axons
and myelin sheath thickness are associated with cognitive impair-
ment. The ﬁndings in the present study are in line with neuroim-
aging studies that show decreased white matter densities in the
prefrontal cortex correlates with decreased reaction time (Gold
et al., 2010), information processing speed (Lu et al., 2011, 2013),
and executive functioning involving attentional set-shifting and
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et al., 2013)]. More importantly, the imaging study results are
consistent whether done in normal aged subjects or cancer survi-
vor patients that received chemotherapy.
A surprising ﬁnding in the present study is the fact that admin-
istration of COX-2 inhibitor did not completely abolish the effects
of CMF on myelination and cognitive function. A possible reason
for these unexpected ﬁndings is that cyclooxygenases derived from
prostaglandin exist in two isoforms COX-1 and COX-2 (Pepicelli
et al., 2005). These two isoforms share 60% homology but may play
different roles in neuroinﬂammation (Phillis et al., 2006). Tradi-
tionally, COX-2 is recognized as the enzyme produced resulting
from an inﬂammatory event even though both isoforms are consti-
tutively expressed in the brain. But recent reports show that COX-1
also plays a role in neuroinﬂammation due to its predominant
location in microglial cells [reviewed in (Aid and Bosetti, 2011)].
Thus, it is possible that by blocking only COX-2 our results show
only partial inhibition of the neuroinﬂammatory response.
Another reason is that recent reports show that COX-2 may also
have an anti-inﬂammatory response (Yang and Chen, 2008). For
example, some studies show that COX-2 deletion increased neuro-
nal damage, glial activation, and the expression of the inﬂammatory
cytokine IL-1b aswell as free radicals (Aid and Bosetti, 2011). There-
fore, it is possible that by administering COX-2 inhibitor to the CMF
rats in the present study we extinguished the protective effects of
COX-2 and instead aggravated the cytotoxic effects of chemother-
apy. However, this seems improbable given that use of COX-2
inhibitor during and after CMF therapy in the present study modu-
lated the neuroinﬂammatory response and the toxic effects of
chemotherapy on myelination and cognitive function.
In sum, our study shows proof of concept that neuroinﬂamma-
tion is involved in CMF-induced cognitive impairment and effects
on myelination. The association between myelination changes in
the corpus callosum and CMF-induced may have be mediated by
the persistent neuroinﬂammation induced by the cytotoxic effects
of chemotherapy. Because CMF-induced cognitive impairment was
not completely abolished by administration of COX-2 inhibitor in
our study, it also raises the possibility that neuroinﬂammation
may not be the only biochemical process triggered by CMF that
can affect myelination and cognition. Future studies on the role
of key growth factors and cellular signaling mechanisms on CMF-
induced cognitive impairment can address this issue.
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